Apelix drug explained: manufacturer, properties and instructions for use

Apelvis (trade name: Piqray) is a targeted kinase inhibitor developed and produced by Novartis Pharmaceuticals. The drug was approved by the US FDA in May 2019, marking a breakthrough in the treatment of breast cancer. As the first hormone receptor-positive (HR+) and human epidermal growth factor receptor PIK3CA mutation. Designed to treat patients with span>2negative (HER2-) advanced or metastatic breast cancer, Apelvis opens a new treatment chapter.

Apelix, as an inhibitor of phosphatidylinositol-3-kinase(PI3K), mainly has significant inhibitory activity against PI3Kα. In breast cancer cell lines, it effectively inhibits the phosphorylation of PI3K downstream targets, including Akt, and exhibits potent activity in cell lines harboring PIK3CA mutations. Studies have confirmed that apelvis can inhibit the PI3K/Akt signaling pathway and reduce tumor growth in xenograft models, including breast cancer models. Of note, PI3K inhibition by apelvis treatment also leads to an increase in estrogen receptor (ER) in breast cancer cells. The combination of apelvis with fulvestrant showed more significant antitumor activity than either treatment alone.

Apelix is a prescription drug and must be used under the strict guidance of a doctor. In general, the recommended dose of this drug is 300 mg orally (that is, two 150 mg tablets) once daily, and is recommended to be taken with food. Patients should swallow the tablet whole and do not chew, break or break the tablet. In response to possible adverse reactions, such as severe hypersensitivity reactions, severe skin reactions, hyperglycemia, pneumonia, and severe diarrhea, doctors may consider adjusting the dosage regimen, including suspending dosage, reducing dosage, or discontinuing medication, to ensure patient safety.

Before taking Apelvis, patients need to confirm the presence of the PIK3CA mutation through an FDA approved diagnostic test. In addition, since Apelvis has embryo-Fetotoxicity, which may cause harm to the fetus, so patients may need a negative pregnancy test before starting treatment. Patients should inform their doctor immediately if they suspect they may be pregnant. For patients of reproductive potential, effective contraceptive measures should be taken.

To sum up, as the first therapeutic drug targeting PIK3CA mutated HR+/HER2- advanced breast cancer, apelvis not only brings new treatment hope to such patients, but also provides clinicians with a clear and effective treatment option. Its unique drug properties and clear method of use make Apelvis show great potential in the treatment of breast cancer. However, patients must strictly follow medical instructions during use and pay close attention to adverse reactions to ensure treatment effectiveness and safety. There are currently different versions of Apelvis available on the market, and patients should choose according to their own needs and doctor's recommendations.